The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for ...

AI has been hailed as a way to speed up historically sluggish drug development, but an entirely AI-designed drug has yet to be approved by the FDA. The furthest along is likely Insilico Medicine’s ...

AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...

Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

British drug discoverer Sygnature Discovery plans to lay off 60 employees in the U.K. and an undisclosed number of staffers in Canada, Fierce Biotech has learned. | British drug discoverer Sygnature ...

Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

As for Chia Tai Feng Hai, the company is owned by parent company Sino Biopharmaceutical, a large Chinese pharma based in Hong ...

Moderna has outlicensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...